In their statement at a recent virtual event titled "COVID-19 and Vaccine Equity: What Can the WTO Contribute?" held on 14 April 2021, the European Union (EU) Commission continued to defend a position that leaves a handful of pharmaceutical companies strongly in control of global production and supply of the vaccines. The EU bloc is one of the few remaining voices still blocking the so-called TRIPS Waiver, which could increase global access to COVID-19 medical tools.
Our team has annotated the statement to analyse the EU's arguments.